Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a mixed financial performance: a 15% revenue increase and improved gross margin are positive, but rising operating expenses and net loss are concerning. The lack of strategic updates and forward-looking caution adds uncertainty. Overall, the sentiment is neutral, reflecting balanced positives and negatives.
Key Financial Performance
Revenue Bionano reported revenue of $8.2 million for Q1 2026, representing a 15% increase year-over-year. This growth was driven by higher adoption of the company's Saphyr system and increased consumable sales.
Gross Margin The gross margin for Q1 2026 was 58%, up from 55% in Q1 2025. The improvement was attributed to better operational efficiencies and a favorable product mix.
Operating Expenses Operating expenses for Q1 2026 were $18.5 million, a 10% increase compared to Q1 2025. The rise was due to higher R&D investments and increased personnel costs.
Net Loss Net loss for Q1 2026 was $12.3 million, compared to $11.5 million in Q1 2025. The increase in net loss was primarily due to higher operating expenses.
Cash and Cash Equivalents Bionano ended Q1 2026 with $45 million in cash and cash equivalents, down from $50 million at the end of Q1 2025. The decrease was mainly due to ongoing investments in R&D and operational activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that actual results may differ materially from forward-looking statements due to several factors and risks, indicating potential challenges in meeting projected outcomes.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Adamchak VP
Albert Luderer
Bionano Conference
CEO Adamchak
Campbell Gilmartin
Chairman Interim
Chen HC
Co LLC
Controller Webb
Division PM
EDT day
Gilmartin Group
Group LLC
HC Wainwright
Interim CEO
LLC Research
LLC Yi
Luderer Chairman
Officer Controller
PM EDT
Research Division
VP Accounting
Wainwright Co
Webb Campbell
Yi Chen
conference Webb
day Bionano
BNGO Transcript
Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call reveals a mixed financial performance: a 15% revenue increase and improved gross margin are positive, but rising operating expenses and net loss are concerning. The lack of strategic updates and forward-looking caution adds uncertainty. Overall, the sentiment is neutral, reflecting balanced positives and negatives.
Bionano Genomics, Inc. (BNGO) Q4 2025 Earnings Call Transcript
Unknown3-23
The earnings call presented mixed signals: a decline in software revenue and geographic narrowing suggest challenges, while improved margins and cost reductions are positive. The Q&A revealed management's reluctance to provide specific guidance, raising uncertainties. However, the expected revenue growth and potential catalysts like the CPT code price increase offer some optimism. Overall, the sentiment is neutral due to balanced positive and negative factors, and without market cap data, a more precise prediction is challenging.
Bionano Genomics, Inc. (BNGO) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings report indicates positive financial performance with revenue growth and improved margins, but there are concerns regarding liquidity constraints and profitability challenges. The Q&A session highlighted uncertainties in achieving target utilization levels and market expansion timelines. Despite a new CPT code and increased system installations, the dependency on routine users and economic uncertainties pose risks. The recent stock offering and restricted cash further temper optimism. Given these mixed signals, the stock price is expected to remain relatively stable over the next two weeks.
Bionano Genomics, Inc. (BNGO) Q2 2025 Earnings Call Transcript
Unknown8-15
The earnings call presents a mixed picture. Financial performance shows a revenue decline but improved margins and cost reductions. Product development highlights growth in flowcell utilization and software adoption. However, market competition and system returns pose risks. The Q&A reveals opportunities for software expansion and strategic partnerships but also highlights uncertainties in system returns and reimbursement pricing. Overall, the sentiment is neutral, reflecting balanced positive and negative factors without a clear catalyst for significant stock price movement.
BNGO Slides
BNGO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
